Current guidelines [10, 12] recommend combining SGLT2 inhibitors and GLP-1 RAs to further reduce cardiorenal risk in individuals with type 2 diabetes and established CVD or multiple cardiovascular risk factors. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.